ZYMEWORKS
Live / Applied — Response to non-final action entered (as of 02 Dec 2025)
What this means for you
Not registered yet, but its 15 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79412060
- Mark type
- Design + words
- Filed
- 15 Oct 2024
- Attorney of record
- Kiranjit K Dharsan
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for regulating the immune system, antibodies, antibody-drug conjugates, and their constituents; medicines for human purposes for the treatment of cancer, autoimmune and autoinflammatory diseases; diagnostic preparations for medical purposes; chemical preparations for pharmaceutical and medical purposes, namely, the treatment and diagnosis of cancer, autoimmune and autoinflammatory diseases; chemical preparations for pharmaceutical and medical purposes, namely, regulating the immune system, antibodies, antibody-drug conjugates, and their constituents; biological preparations for medical and pharmaceutical purposes, namely, biologic and recombinant therapeutic agents comprised of monoclonal antibodies, multispecific and bispecific antibodies, antibody fragments, antibody-drug conjugates, fusion proteins, recombinant proteins, cytokines, peptides, and nucleic acid-based biologics and their constituents, derivatives, variants, conjugates, and formulations; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of cancer; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of human autoimmune diseases, disorders and conditions; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of human inflammatory diseases, disorders and conditions
- Class 042 — Scientific and technological services: Chemical, biochemical and biological research and analysis; research and development in the field of biotechnology; medical and pharmacological research services and product development in the field of biologics, proteomics, and antibody engineering; pharmaceutical products development and pharmaceutical product evaluation; scientific research in the nature of conducting clinical trials for others for pharmaceutical products; scientific research and development of preparations, agents and technology for the development of antibody therapeutics for the treatment, and prophylaxis of human diseases, disorders and conditions, namely, cancer, auto immune and inflammatory diseases; providing scientific information to scientists, physicians and health care providers in the fields of cancer, auto immune diseases, inflammatory diseases, and infectious diseases; chemical molecular analysis provided to pharmaceutical, biotechnology and chemical industries using proprietary software and proprietary analytical tools and algorithms; product optimization services, namely, research and development services of new pharmaceutical products provided to pharmaceutical, biotechnology and chemical industries using proprietary software and proprietary analytical tools and algorithms
- Class 045 — Legal and security services: Intellectual property licensing services
Owner
Prosecution history
- 02 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 21 Jun 2025 — REFUSAL PROCESSED BY IB
- 03 Jun 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 03 Jun 2025 — REFUSAL PROCESSED BY MPU
- 01 Apr 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 31 Mar 2025 — NON-FINAL ACTION WRITTEN
- 24 Mar 2025 — ASSIGNED TO EXAMINER
- 13 Dec 2024 — APPLICATION FILING RECEIPT MAILED
- 13 Dec 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 12 Dec 2024 — SN ASSIGNED FOR SECT 66A APPL FROM IB